AZ AND LILLY ALLIANCE TO DEVELOP BACE INHIBITOR

ASTRAZENECA AND LILLY ANNOUNCE ALLIANCE TO DEVELOP AND COMMERCIALISE BACE
INHIBITOR AZD3293 FOR ALZHEIMER'S DISEASE

AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to
jointly develop and commercialise AZD3293, an oral beta secretase cleaving
enzyme (BACE) inhibitor currently in development as a potential treatment for
Alzheimer's disease.

The progression of Alzheimer's disease is characterised by the accumulation of
amyloid plaque in the brain, which is comprised of peptides called amyloid beta.
BACE is an enzyme associated with the development of amyloid beta. Inhibiting
BACE is expected to prevent the formation of amyloid plaque and eventually slow
the progression of the disease. AZD3293 is an oral, potent and selective small
molecule inhibitor of BACE that has been shown in Phase I studies to
significantly and dose-dependently reduce levels of amyloid beta in the cerebro
-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca
announced earlier in 2014 its plan to move AZD3293 into registration trials.

Under the terms of the agreement, Lilly will pay AstraZeneca up to $500 million
in development and regulatory milestone payments. AstraZeneca expects to receive
the first milestone payment of $50 million in the first half of 2015. The
companies will share all future costs equally for the development and
commercialisation of AZD3293, as well as net global revenues post-launch.

AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III
clinical trial in patients with early Alzheimer's disease. Lilly will lead
clinical development, working with researchers from AstraZeneca's Innovative
Medicines Unit for neuroscience, while AstraZeneca will be responsible for
manufacturing. The companies will take joint responsibility for
commercialisation of AZD3293.

Mene Pangalos, Executive Vice President, Innovative Medicines & Early
Development at AstraZeneca, said: "Alzheimer's disease is one of the biggest
challenges facing medical science today and BACE inhibitors have the potential
to target one of the key drivers of disease progression. We are looking forward
to working with Lilly, an organisation with a long term commitment to and
expertise in treating Alzheimer's disease. We believe that, by combining the
scientific expertise from our two organisations and by sharing the risks and
cost of late stage development, we will be able to accelerate the advancement of
AZD3293 and progress a promising new approach to support the treatment of
Alzheimer's patients around the world.

"What's more, this alliance will enable AstraZeneca to further sharpen our
strategic focus on core therapeutic areas, while leveraging external
collaborations to maximise the potential of the strong science we have in our
growing pipeline."

"Lilly has been committed to research in Alzheimer's disease for more than 25
years, and we're dedicated to developing new medicines that can change and
modify the course of this devastating disease," said David Ricks, Lilly Senior
Vice President and President, Lilly Bio-Medicines. "Lilly's pipeline of
potential medicines and diagnostic agents targeting the known hallmarks of the
disease has been bolstered today by this alliance with AstraZeneca, which shares
our passion to bring new medicines to patients suffering from this debilitating
illness. This alliance moves us one step closer to achieving our goal of making
Alzheimer's dementia preventable by 2025."

The agreement is subject to customary terms and conditions. It will have no
impact on AstraZeneca's 2014 Core Earnings per Share.

About AZD3293

AZD3293 is an oral, potent and selective small molecule inhibitor of BACE that
has been shown in Phase I studies to significantly and dose-dependently reduce
levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and
healthy volunteers.

About Alzheimer's disease

Alzheimer's disease is a fatal illness that causes progressive decline in memory
and other aspects of cognition. It is the most common form of dementia,
accounting for 60 to 80 percent of dementia cases. According to the Alzheimer's
Association, there are currently an estimated 44 million people living with
dementia worldwide. The number of people affected by dementia is expected to be
more than 75 million in 2030 and 135 million in 2050.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than a century ago
by a man committed to creating high-quality medicines that meet real needs, and
today we remain true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to those who need
them, improve the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more about Lilly,
please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)

Jacob Lund                                  +46 8 553 260 20 (Sweden)

Michele Meixell                            + 1 302 885 6351 (US)

Investor Enquiries

Karl Hård                                    +44 20 7604 8123  mob: +44 7789
654364

Jens Lindberg                                                               mob:
+44 7557 319729

Anthony Brown                            +44 20 7604 8067    mob: +44 7585
404943

Eugenia Litz                                +44 20 7604 8233    mob: +44 7884
735627

16 September 2014

-ENDS-